Accreditation
Overview
Accommodations
Faculty
Opportunities
Multimedia
Registration
Resources
View Archive

1st Annual European Congress on Immunotherapies in Cancer™

1st Annual European Congress on Immunotherapies in Cancer™


23-24 September 2016
W Barcelona
Barcelona, Spain


Overview

The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. In addition to landmark data on the integration of new strategies into evolving treatment paradigms, preclinical and clinical data continue to rapidly accumulate on immunotherapy basic science.

However, the rapidity of the changes in the field and information that continues to emerge create practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence on immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.

The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on science advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.

2016 Can't-Miss Topics

  • State-of-the-art immunotherapy: basic science updates
  • Checkpoint blockade: Where are we now? Where are we going?
  • Updates in clinical immunotherapy across tumor types (lung, head and neck, melanoma, lymphoma, breast, gynecological, gastrointestinal, and genitourinary) 
  • Practical challenges in expanding and commercializing immunotherapy platforms
  • Integrating available immunotherapeutics into standard approaches
  • Modulating the tumor-microenvironment-immune system interface
  • Finding synergy: immunotherapy-containing combination therapy
  • Incorporating biomarkers into trials versus practice
  • Overcoming resistance

 

Program Chair
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Co-Chair
Roman Perez-Soler, MD 
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, New York, USA

European Planning Committee
Joan Carles, MD, PhD
Associate Professor of Medicine. UIC
Director GU, CNS and Sarcoma Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
 
Enriqueta Felip, MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
 
Jose A Lopez-Martin, MD, PhD
Chairman, GETICA (Grupo Español de Terapias Inmuno-Biologicas en Cancer / Spanish Group for Cancer Immuno-Biotherapy)
Early Clinical and Translational Research Unit
Sarcoma & Melanoma Programme
Medical Oncology Department,
'12 de Octubre' University Hospital
Madrid, Spain
 
Aleix Prat, MD, PhD
Head of the Medical Oncology Department
Hospital Clinic
Associate Professor
University of Barcelona
Head of the Translational Genomics Group
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Faculty
Joaquim Bellmunt, MD, PhD
Director, Bladder Cancer Center
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA
 
Dr. Thomas Blankenstein
Research Group Leader, Max-Delbrück-Center for Molecular Medicine (MDC)
Director, Institute for Immunology, Charité – Universitätsmedizin
Berlin, Germany
 
George Coukos, MD, PhD
Director, Lausanne Branch
Ludwig Institute for Cancer Research
Lausanne, Switzerland
 
Alena Gros, PhD
Group Leader, Tumor Immunology and Immunotherapy Group
Vall d'Hebron Institute of Oncology (V.H.I.O.)
Barcelona, Spain
 
John B.A.G. Haanen, MD, PhD
Head of the Division of Medical Oncology and
Staff Scientist in the Division of Immunology
The Netherlands Cancer Institute
Amsterdam, Netherlands
Professor of Translational Immunotherapy of Cancer
Leiden University Medical Center
 
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania, USA
 
Ronald Levy, MD
Professor
Division of Oncology
Stanford School of Medicine
Stanford, California, USA
 
David F. McDermott, MD
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Director, Biologic Therapy and Cutaneous Oncology Programs, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA
 
Sergio Quezada, PhD
Group Leader, Immune Regulation and Tumor Immunotherapy Lab
University College London Cancer Institute
London, United Kingdom
 
Caroline Robert, MD, PhD
Head of the Dermatology Unit, Department of Medicine
Gustave Roussy and Paris Sud University
Villejuif Grand-Paris, France
 
Jacob Schachter, MD
Head – The Ella Lemelbaum Institute for Melanoma
Division of Oncology
Sheba Medical Center
Tel Hashomer, Israel
 
Peter Schmid, FRCP, MD, PhD
Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute, Queen Mary University of London
Director, Barts Breast Centre, Barts Hospital London
London, United Kingdom
 
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Vall d' Hebron University Hospital
Vall d'Hebron Institute of Oncology (V.H.I.O.)
Barcelona, Spain
 

Target Audience

This educational activity is intended for healthcare professionals based outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.


Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain mechanistic approaches toward targeting the immune system to treat cancer
  • Evaluate the clinical applicability of data from clinical trials of immunotherapy strategies
  • Discuss methods to individualize the use of immunotherapy strategies, including the use of biomarkers
  • Describe how to proactively mitigate and manage adverse events associated with the use of treatment strategies used in the care of patients with cancer
  • Identify unmet clinical needs in cancer treatment and highly anticipated clinical trials evaluating novel immunotherapeutic approaches



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


In case of onsite emergency:

Professional Information


Specialties*

Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By